Results 61 to 70 of about 38,719 (198)

Fallopian Tube Neoplasm [PDF]

open access: hybrid, 2020
National Cancer Institute
openalex   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos   +6 more
wiley   +1 more source

Fibroids in obstructed hemivagina and ipsilateral renal anomaly‐like syndrome: Successful hysterectomy and vaginal septoplasty in a kidney transplant recipient with uterus didelphys, vaginal septum and renal agenesis

open access: yes
International Journal of Gynecology &Obstetrics, EarlyView.
Mariana Correia Moreira Cruz   +5 more
wiley   +1 more source

Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis

open access: yesImmunology, EarlyView.
Microbial imbalance, dysbiosis, plays a role in ovarian carcinogenesis by interacting with the immune system and altering inflammatory pathways, notably Th17 pathways. In contrast, eubiosis, characterised by Lactobacillus dominance, protects against infections and maintains hormone metabolism.
Wafa Babay   +4 more
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman   +15 more
wiley   +1 more source

Uterine and Adnexal Metastasis of Lung Adenocarcinoma: 
A Case Report and Literature Review

open access: yesChinese Journal of Lung Cancer
Primary bronchial lung cancer, commonly known as lung cancer, is one of the malignant tumors with high morbidity and mortality in the world. In recent years, the incidence of lung cancer in women has increased, and most of them are lung adenocarcinoma ...
Jiangyan GUO   +5 more
doaj   +1 more source

Doppel as an early‐stage biomarker promoting EMT and dissemination in ovarian cancers

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1755-1768, 15 March 2026.
What's new? Existing biomarkers for ovarian cancer (OC) lack the sensitivity and specificity needed to consistently distinguish the malignancy from non‐ovarian influences and other cancers. Here, the authors explored the ability of the prion‐like protein Doppel, normally found in the male testes, to detect OC.
Zulfikar Azam   +18 more
wiley   +1 more source

Detecting FR‐⍺ Expression Level in Cytology Effusion Specimens From Ovarian Cancer and Comparing It With Tissue Specimens

open access: yesDiagnostic Cytopathology, Volume 54, Issue 3, Page 197-205, March 2026.
ABSTRACT Background Folate receptor‐⍺ (FR‐⍺) is an attractive target for targeted therapy. Mirvetuximab soravtansine (MIRV) has been approved by the United States Food and Drug Administration (FDA) for treating adult patients with FR‐⍺ positive, platinum‐resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Therefore,
Yadan Ma   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy